Acute stroke management in patients taking dabigatran

CNS Neurosci Ther. 2012 Aug;18(8):616-22. doi: 10.1111/j.1755-5949.2012.00329.x. Epub 2012 Apr 25.

Abstract

Dabigatran etexilate is emerging as an alternative for vitamin K antagonists, but evidence-based guidelines for management of intracerebral hemorrhage and acute ischemic stroke in patients taking this drug are nonexistent. This review summarizes current knowledge on key pharmacological features and the assessment of dabigatran activity. Pragmatic approaches are provided for individualized decision taking with regard to hemostatic therapy and reperfusion strategies in acute stroke patients.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Anticoagulants / antagonists & inhibitors
  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use*
  • Benzimidazoles / antagonists & inhibitors
  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use*
  • Blood Coagulation Disorders / chemically induced
  • Blood Coagulation Disorders / drug therapy
  • Case Management
  • Cerebral Hemorrhage / blood
  • Cerebral Hemorrhage / drug therapy
  • Cerebral Infarction / drug therapy
  • Dabigatran
  • Guidelines as Topic
  • Hemostasis / drug effects
  • Hemostatics / therapeutic use
  • Humans
  • Off-Label Use
  • Pyridines / antagonists & inhibitors
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Renal Dialysis
  • Reperfusion
  • Stroke / drug therapy*
  • Vitamin K / antagonists & inhibitors

Substances

  • Anticoagulants
  • Benzimidazoles
  • Hemostatics
  • Pyridines
  • Vitamin K
  • Dabigatran